← Back to Clinical Trials
Recruiting NCT06085300

NCT06085300 The Relationship Between Child Language Proficiency and Language of Treatment on the Outcomes of Bilingual Children with Developmental Language Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06085300
Status Recruiting
Phase
Sponsor University of Houston
Condition Developmental Language Disorder
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2023-08-08
Primary Completion 2028-05-01

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
Sentence recast

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2023-08-08 with a primary completion date of 2028-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Of the 12 million children in the USA growing up bilingual, about 1 million experience Developmental Language Disorder (DLD), a disorder in language learning and use. Currently there is no guidance for speech language pathologists (SLPs) as to the language of intervention for bilingual children with DLD with differing degrees of proficiency with English or Spanish. This project will examine the relationship between relative language proficiency and the language of intervention, considering monolingual intervention in English and Spanish and bilingual intervention presented by alternating English and Spanish treatment sessions with the goal of improving language outcomes and thereby strengthening long-term academic achievement.

Eligibility Criteria

Inclusion Criteria: 1. parent concerns and/or a history of receiving services in the public schools 2. age-specific cutoffs for the morphosyntax subtests for their best language (English or Spanish) on the Bilingual English Spanish Assessment. The cut-off score for best language for 4-year-olds is 84, for 5-year-olds is 85, and for 6-year-olds is 81. Using the best-language approach, these scores have a sensitivity over 90% and specificity over 80% for children between 4;0 and 6;11 years of age , which is considered acceptable for studies of diagnostic accuracy. 3. nonverbal IQ, as measured by the Kaufman Brief Intelligence Test-2, matrices subtest, will be at or above a standard score of 70. 4. pass a hearing screening test 5. participants must be bilingual, that is children must be producing at least simple sentences in spontaneous speech in both Spanish and English, or understand English and Spanish. 6. participants must be able to benefit from treatment for both conditional adverbial clauses and complement clauses, as evidenced by accuracy below 40% on 10-item elicited production probes in both languages Exclusion Criteria: * 1\) children with significant sensory-motor concerns or psychiatric disorders per parent report will not be enrolled.

Contact & Investigator

Central Contact

Anny Castilla-Earls

✉ annycastilla@uh.edu

📞 713-743-0488

Frequently Asked Questions

Who can join the NCT06085300 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, up to 6 Years, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06085300 currently recruiting?

Yes, NCT06085300 is actively recruiting participants. Contact the research team at annycastilla@uh.edu for enrollment information.

Where is the NCT06085300 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT06085300 clinical trial?

NCT06085300 is sponsored by University of Houston. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology